Business Wire

VERTIGIS

10.3.2022 07:02:11 CET | Business Wire | Pressemeddelelse

Del
EDP sluttes sammen med VertigGIS og åbner nordisk marked

VertigGIS, en førende udbyder og softwareudvikler af geografiske informationssystemer (GIS), har gennemført erhvervelsen af 100 % af EDP Consult AB, en etableret leverandør af software og services med base i Staffanstorp i Sverige.

Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20220309005032/da/

VertiGIS støttes af et globalt investeringsselskab med fokus på teknologi, Battery Ventures, der i 2017 begyndte at erhverve softwarevirksomheder inden for GIS- og positionsteknologi under sit varemærke.

EDP, der er bedst kendt for produkterne EDP Future, EDP Mobile og EDP Vision, udvikler og leverer software til svenske kommuner. Virksomhedens teknologi håndterer specifikt kundens udfordringer inden for vand og affald, fjernvarme, leje og generel fakturering samt sagsovervågning og dokumentstyring for alle dele af den offentlige administration, offentlige styrelser og virksomheder.

EDP's stifter og administrerende direktør Mikael Nyquist forklarer: "Jeg er stolt over det, som mine EDP-kolleger har opnået i løbet af de seneste 39 år, og jeg er spændt på at se, hvordan vi vil udvikle os og tilbyde vores kunder ny værdi som en del af VertiGIS."

EDP bliver partner i VertiGIS' eksisterende virksomhed inden for den offentlige sektor, der har årtiers dokumenteret ekspertise i at hjælpe kommuner med at løse lignende udfordringer på dets respektive markeder.

"EDP's kundeorienterede tilgang til digitalisering af processer og løsning af udfordringer med positionsteknologi passer godt til vores," tilføjer Richard Wiegmann, President & CEO for VertigGIS. "Vi er glade for at få EDP med i VertiGIS og ser frem til at være med til at tilbyde deres ekspertise til nye kunder over hele verden, samtidig med at vi finder muligheder for eksisterende VertiGIS-teknologi på det nordiske marked."

EDP's produktlinjer slås sammen med VertiGIS’ løsninger til offentlig sektor- og arealforvaltning, forsyning og energi, telekommunikation og infrastruktur- og ejendomsadministration, der betjener mere end 5.200 kunder over hele verden.

Om VertiGIS:

VertiGIS er førende udbyder og softwareudvikler inden for geografiske informationssystemer (GIS). Virksomheden har fokus på udvikling af softwareløsninger og tjenester, der hjælper kunder inden for forsyning og energi, arealforvaltning, den offentlige sektor, telekommunikation samt branchekunder med at koble deres forretningsprocesser sammen med positionsteknologi. Produktporteføljen fra VertiGIS anvendes af tusindvis af kunder og millioner af slutbrugere i over 50 lande og er designet til at forbedre egenskaberne ved førende kortlægningssoftware, især ESRI's ArcGIS®. De vigtigste produktmærker omfatter: VertiGIS Studio, UT for ArcGIS®, 3A produktlinjen, GEONIS, ConnectMaster™, M4® Solutions, GeoOffice, WebOffice, ProOffice og EDP-produkterne Future, Mobile og Vision. Få mere at vide påwww.vertigis.com .

Om EDP:

Mere end 90 % af Sveriges kommuner driver deres daglige virksomhed ved hjælp af software fra EDP. Ved at arbejde tæt sammen med svenske kommuner, statslige styrelser og store virksomheder udvikler EDP sammenhængende, funktionelle og tidsbesparende IT-løsninger til den offentlige sektor. EDP-software anvendes på flere forskellige forretningsområder, f.eks. affaldshåndtering og styring af byggetilladelser, og bidrager til et velfungerende digitalt samfund, der er tilgængeligt for alle. Få mere at vide på www.edp.se .

Om Battery Ventures:

Battery bidrager med exceptionelle stiftere og ledelsesteams og udvikler kategoridefinerende virksomheder på markeder såsom software og services, virksomhedsinfrastruktur, onlinemarkeder, sundheds-IT og industriteknologi. Virksomheden blev stiftet i 1983 og støtter virksomheder på alle stadier, lige fra seed-kapital og tidligt i processen til vækst og overtagelse, og investerer globalt fra kontorer i Boston, San Francisco og Menlo Park, Californien, Herzliya, Israel; London og New York. Følg firmaet på Twitter @BatteryVentures, besøg vores hjemmeside på www.battery.com , og se en komplet liste over selskaberne i Batterys portefølje her .

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye